Technology
Health
Biotechnology

Proteostasis Therapeutics

$4.30
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.03 (-0.69%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell PTI and other stocks, options, ETFs, and crypto commission-free!

About

Proteostasis Therapeutics, Inc. Common Stock, also called Proteostasis Therapeutics, is a clinical stage biopharmaceutical company, which engages in the discovery and development of novel therapeutics to treat cystic fibrosis (CF), and other diseases caused by an imbalance in the proteostasis network. Read More The company was founded by William Balch, Jeffery W. Kelly, Andrew Dillin, Richard I. Morimoto, Alfred Lewis Goldberg, Daniel Finley, Christopher T. Walsh, and Randall W. King in 2006 and is headquartered in Boston, MA.

Employees
48
Headquarters
Boston, Massachusetts
Founded
2006
Market Cap
220.00M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
1.26M
High Today
$4.38
Low Today
$4.23
Open Price
$4.28
Volume
201.10K
52 Week High
$10.38
52 Week Low
$1.71

Collections

Technology
Health
Biotechnology
Therapy
Pharmaceutical
2016 IPO
US
North America

News

Simply Wall StMar 12

Are Insiders Buying Proteostasis Therapeutics, Inc. (NASDAQ:PTI) Stock?

We’ve lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip side of that is that there are more than a few examples of insiders dumping stock prior to a period of weak performance. So shareholders might well want to know whether insiders have been buying or selling shares in Proteostasis Therapeutics, Inc. (NASDAQ:PTI). What Is Insider Buying? It is perfectly legal for company insiders, including board members, to buy and sell stock in a comp...

377
MarketBeatMar 5

Stock Price, News, & Analysis for Proteostasis Therapeutics

Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops novel therapeutics to treat cystic fibrosis and other diseases caused by an imbalance in the proteostasis network. Its lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class, which is in Phase II study. The company is also involved in developing PTI-801, a corrector molecule; and PTI-808, a potentiator molecule t...

27
Guru FocusFeb 25

Detailed Research: Economic Perspectives on Novartis AG, Proteostasis Therapeutics, Williams-Sonoma, Magna International, YRC Worldwide, and Delek Logistics Partners — What Drives Growth in Today's Co

NEW YORK, Feb. 25, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Novartis AG (:NVS), Proteostasis Therapeutics, Inc. (NASDAQ:PTI), Williams-Sonoma, Inc. (:WSM), Magna International Inc. (:MGA), YRC Worldwide, Inc. (NASDAQ:YRCW), and Delek Logistics Partners, L.P. (:DKL), including updated fundamental summaries, consolidated fiscal reporting, and fully-qu...

153

Earnings

-$0.72
-$0.59
-$0.45
-$0.32
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.37 per share
Actual
Expected Mar 25, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.